sur Mainz BioMed N.V.
Mainz BioMed Releases Mid-Year 2024 Financial Results
Mainz BioMed N.V., a molecular genetics diagnostic firm, shared its mid-year 2024 financial performance and company updates. The company reported a 4% increase in revenue year-over-year and a 32% reduction in loss from operations. These outcomes stem from efficiency improvements.
The company achieved significant milestones in the first half of the year. Notably, pooled results from the ColoFuture and eAArly DETECT studies were published at ASCO, displaying exceptional sensitivity for colorectal cancer at 92% and 82% for advanced adenomas. Additionally, Mainz Biomed enhanced its ColoAlert® product to optimize lab processes and reduce retesting rates.
Moving forward, the company plans to focus on expanding ColoAlert® in Europe, advancing a new colorectal cancer screening product, and conducting a 2,000 patient study in the U.S. The feedback from the FDA supports these initiatives.
R. H.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Mainz BioMed N.V.